Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
South Korea’s KOSPI Plunges as Apple Price Hikes and OpenAI IPO Delay Shake AI Chip Stocks 
Gold Prices Rise Above $4,000 as Inflation Data and Weaker Dollar Boost Demand 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
RFK Jr. Faces Scrutiny Over David Geier’s HHS Role and Vaccine Review Work 
The four types of dementia most people don’t know exist 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
